![](https://thepharmadata.com/wp-content/uploads/2024/07/Autobahn-Therapeutics-Raises-100-Million-in-Oversubscribed-Series-C-for-CNS-Disorder-Treatments_11zon-768x512.webp)
Autobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments
Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners and included new investors Canaan Partners, Monograph Capital, and…